{"meta":{"query_hash":"cb40d4be59b0","filters":{"venue":"Journal of Dermatologic Research And Therapy"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/cb40d4be59b0","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Dermatologic+Research+And+Therapy"},"results":[{"id":"W2773756552","doi":"10.14302/issn.2471-2175.jdrt-17-1760","title":"Blockade of Programmed Cell Death Protein-1 Pathway for the Treatment of Melanoma","year":2017,"lang":"en","type":"article","venue":"Journal of Dermatologic Research And Therapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nivolumab; Pembrolizumab; Ipilimumab; Medicine; Melanoma; Dacarbazine; Oncology; Internal medicine; Blockade; Cancer; Adverse effect; Immune checkpoint; PD-L1; Immunotherapy; Cancer research","score_opus":0.1412676086609013,"score_gpt":0.3993332796148271,"score_spread":0.25806567095392585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773756552","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04633035,0.92778647,0.0050162636,0.0043766676,0.0011336367,0.00010781987,0.00012688713,0.00021040943,0.01491151],"genre_scores_gemma":[0.4025417,0.5765513,0.005365427,0.002049735,0.0010347577,0.00009808027,0.0003168275,0.000026006115,0.012016197],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99993086,0.000016339149,0.000005548009,0.0000099714,0.000025845227,0.000011302029],"domain_scores_gemma":[0.99996483,0.000006860898,0.0000098398805,0.0000025773847,0.000007754342,0.000008062793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020281768,0.00018457447,0.00021724199,0.00035975123,0.00012978024,0.00028043575,0.00015189189,0.00022612457,0.001647438],"category_scores_gemma":[0.00013715544,0.000048117003,0.0002987831,0.00016028334,0.00015752786,0.00024916884,0.00020750052,0.00095528946,0.00043102255],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006522784,0.0004991141,0.00088661135,0.002208722,0.00011284507,0.00058546796,0.000059616155,0.0004756969,0.088603646,0.004370347,0.017725423,0.8838202],"study_design_scores_gemma":[0.00090335956,0.005145995,0.010318308,0.0010742024,0.00036507138,0.011239007,0.00009417254,0.0021310241,0.1048369,0.006699604,0.857132,0.00006027709],"about_ca_topic_score_codex":0.00013138186,"about_ca_topic_score_gemma":0.0004964761,"teacher_disagreement_score":0.001647438,"about_ca_system_score_codex":0.00021464059,"about_ca_system_score_gemma":0.00025148754,"threshold_uncertainty_score":0.0055112243},"labels":[],"label_agreement":null}]}